Innovent Biologics
Innovent Biologics engages in research and development of monoclonal antibody drugs for cancer and autoimmune diseases.
Business Model:
Revenue: $588.9M
Employees: 1,001-5,000
Rankings
Industries / Tags:
Detailed Innovent Biologics Information
Geographic Data
Address: 168 Dongping Street
City: Suzhou
State: jiangsu province
Zip: 215123
Country: CN
Financial Info
Stage:
post ipo equity
Raised Last:
$308M
Raised Total:$868M
Social
Metrics
1,355,465Website Global Rank
20,738Website Monthly Traffic
Twitter Followers
Description
Innovent Biologics engages in research and development of monoclonal antibody drugs for cancer and autoimmune diseases.
Contact Phone:
Contact Email:
Innovent Biologics went public on 10/24/2018 on the Hong Kong Stock Exchange
Listed Exchange:
Hong Kong Stock Exchange
IPO Date:
10/24/2018
IPO Valuation:
$2B
Ticker Symbol:
1801
IPO Price:
$1.7830586470691772/share
Amount Raised:
$421M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2021 | AnHeart Therapeutics | Series B | 0 |
| 12/2021 | AnHeart Therapeutics | Series B | 0 |
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
